反应适应性超低剂量4 Gy放疗作为胃MALT淋巴瘤根治性治疗:单中心先导试验
这项单中心、单臂、前瞻性先导试验在MD安德森癌症中心纳入24例新诊断或复发的幽门螺杆菌阴性胃MALT淋巴瘤患者(I-IV期),给予4 Gy分两次放疗,按反应适应性策略决定是否追加20 Gy。4 Gy后20例(83%)达完全缓解,3年局部控制率96%(95%CI 88-100),无3级及以上不良事件。
要点
- 4 Gy分两次放疗后20例(83%)达完全缓解,3年局部控制率96%(95%CI 88-100)。
- 4例需追加20 Gy者均在12个月内达完全缓解。
- 最常见不良事件为1级恶心(4 Gy组9/24,20 Gy组2/4)和1级腹痛(5/24和0/4),无3级及以上事件。
核心结论
- 多数患者4 Gy放疗后达完全缓解,所有需追加20 Gy者在12个月内达完全缓解。
- 作者认为该反应适应性策略可用于筛选能从追加放疗中获益的患者,并使其他患者免于潜在相关毒性。
研究设计与样本
- 单中心、单臂、前瞻性先导试验,在MD安德森癌症中心(美国休斯顿)开展。
- 纳入18岁及以上、新诊断或复发的幽门螺杆菌阴性胃MALT淋巴瘤、I-IV期患者,因预期毒性低未将体能状态作为排除标准。
- 患者接受外照射光子放疗,总剂量4 Gy分两次;3-4个月内镜和影像达完全缓解者观察,部分缓解者6-9个月再评估;9-13个月残留病灶或任何时间疾病稳定或进展者追加20 Gy。
- 主要终点为4 Gy治疗后1年(第二次评估时间点)胃完全缓解率,按意向治疗分析;试验注册号NCT03680586,已完成并停止入组。
主要发现
- 2019年3月27日至2021年10月12日共入组24例符合条件患者,中位年龄67岁(IQR 58-74;范围40-85);女性15例(63%),男性9例(37%);白人18例(75%),亚裔4例(17%),西班牙裔2例(8%);I期20例(83%),II期1例(4%),IV期3例(13%)。
- 中位随访36个月(IQR 26-42);20例(83%)对4 Gy达完全缓解(16例在3-4个月,4例在9-13个月)。
- 2例因3-4个月症状性稳定疾病接受20 Gy,2例因9-13个月残留病灶接受20 Gy,所有4例均达完全缓解。
- 3年局部控制率96%(95%CI 88-100);1例在4 Gy放疗后14个月局部复发,经20 Gy成功挽救;1例IV期患者出现远处复发。
- 最常见不良事件为1级恶心(接受4 Gy的24例中9例[38%],接受20 Gy的4例中2例[50%])和1级腹痛(分别为24例中5例[21%]和4例中0例);无3级或更差不良事件,包括无治疗相关死亡。
临床怎么用
- 作者认为该反应适应性策略可用于筛选能从追加放疗中获益的患者,并使其他患者免于潜在相关毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the favourable prognosis of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, treatment-related toxicity should be minimised. We aimed to evaluate the efficacy of 4 Gy radiotherapy given in a response-adapted approach. METHODS: We conducted a single-centre, single-arm, prospective trial at MD Anderson Cancer Center (Houston, TX, USA) of response-adapted ultra-low-dose radiotherapy. Eligible patients were 18 years or older and had newly diagnosed or relapsed Helicobacter pylori-negative gastric MALT lymphoma, with stage I-IV disease. Given the expected low toxicity profile of treatment, performance status was not an exclusion criterion. Patients received external beam photon-based radiotherapy for a total dose of 4 Gy in two fractions. Patients with a complete response to 4 Gy via endoscopy and imaging at 3-4 months were observed; patients with a partial response were re-evaluated in 6-9 months. Residual disease at 9-13 months or stable or progressive disease at any time required additional treatment with 20 Gy. The primary endpoint was gastric complete response at 1 year (second evaluation timepoint) after 4 Gy treatment. All analyses were performed as intention to treat. This trial is registered at ClinicalTrials.gov (NCT03680586) and is complete and closed to enrolment. FINDINGS: Between March 27, 2019, and Oct 12, 2021, we enrolled 24 eligible patients. The median age of participants was 67 years (IQR 58-74; range 40-85); 15 (63%) were female and nine (37%) male; 18 (75%) were White, four (17%) Asian, and two (8%) Hispanic; 20 (83%) had stage I disease, one (4%) stage II, and three (13%) stage IV. Median follow-up time was 36 months (IQR 26-42). 20 patients (83%) had a complete response to 4 Gy (16 at 3-4 months, four at 9-13 months); two patients received 20 Gy for symptomatic stable disease at 3-4 months and two for residual disease at 9-13 months; all had a complete response. The 3-year local control rate was 96% (95% CI 88-100), with one local relapse at 14 months after 4 Gy radiotherapy salvaged successfully with 20 Gy. One patient with stage IV disease had a distant relapse. The most common adverse events were grade 1 nausea (nine [38%] of 24 patients who received 4 Gy and two [50%] of four patients who received 20 Gy) and grade 1 abdominal pain (five [21%] of 24 and zero of four, respectively). No grade 3 or worse adverse events were noted, including no treatment-related deaths. INTERPRETATION: Most patients had a complete response after 4 Gy radiotherapy; all who required an additional 20 Gy had a complete response within 12 months. This response-adapted strategy could be used to select patients who would benefit from additional radiotherapy and spare others potential associated toxicity. FUNDING: National Cancer Institute.
引用
- Gunther JR, Xu J, Bhutani MS, et al. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol. 2024. PMID: 38843856. doi:10.1016/S2352-3026(24)00133-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。